Suche Struktur Suche
wx_img
Inquiry Form
  1. Home
  2. Pelabresib

Pelabresib

MorphoSys’ phase 3 study of Pelabresib in myelofibrosis demonstrates statistically significant improvement in spleen volume reduction and strong positive trend in symptom reduction.
Pelabresib (CPI-0610) is an investigational selective small molecule designed to promote anti-tumor activity by inhibiting the function of bromodomain and extra-terminal domain (BET) proteins to decrease the expression of abnormally expressed genes in cancer. MorphoSys intends to submit for approval in the U.S. and Europe in mid-2024.

Methyl 2-iodobenzoate
Methyl 2-iodobenzoate
CM147852
610-97-9
(3-Methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazol-5-yl)methyl acetate
(3-Methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazol-5-yl)methyl acetate
CM208606
1380089-34-8
(4-Bromo-3-methylisoxazol-5-yl)methyl acetate
(4-Bromo-3-methylisoxazol-5-yl)methyl acetate
CM249144
1380089-33-7
1,1-Dimethylethyl (4S)-5,6-dihydro-1-methyl-6-oxo-4H-isoxazolo[5,4-d][2]benzazepine-4-acetate
1,1-Dimethylethyl (4S)-5,6-dihydro-1-methyl-6-oxo-4H-isoxazolo[5,4-d][2]benzazepine-4-acetate
CM1074974
1380089-99-5
3-Methyl-4-phenylisoxazol-5-amine
3-Methyl-4-phenylisoxazol-5-amine
CM281124
4416-71-1
Methyl 2-[5-(hydroxymethyl)-3-methyl-1,2-oxazol-4-yl]benzoate
Methyl 2-[5-(hydroxymethyl)-3-methyl-1,2-oxazol-4-yl]benzoate
CM1074977
2086298-52-2